Abstract
To investigate the role of CD27 in multiple myeloma (MM), bone marrow samples from 130 newly diagnosed MM cases were analysed by 8-colour flow cytometry. CD27- group (n=52) had higher level of β2-MG (5.68 vs 3.20 mg/L, p< 0.05), calcium (2.48 vs 2.20 mmol/L, p< 0.05) as well as higher percentage of ISS stage III (48.72% vs 28.85%, p< 0.05) and high-risk cytogenetics (51.28% vs 40.38%, p < 0.05) than CD27+ group (n=78). After 4 cycles of chemotherapy, the overall response rate and complete remission rate in the CD27- group were both lower than those in the CD27+ group (62.50% vs 76.19%, 7.81% vs 16.67%, respectively; p<0.05).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
